Surgery Partners, Inc. (SGRY) stock
SGRYNasdaqServices-General Medical & Surgical Hospitals, NECFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026Score 6/306% above fair value
$23.21+0.00 (0.00%)
Close on Oct 30, 2026Market cap $3.04BP/E –Yield –
Earnings
Surgery Partners's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 9, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$848.90M
+2.7% on a year earlier
Adjusted net income (loss) per share attributable to common stockholders Diluted, Q2 FY2026
$0.10
$0.17 a year earlier
Latest guidance
Reaffirmed
Aug 10, 2026 · 2 items
Quarterly results
Revenue and earnings per share from each of Surgery Partners's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026before the open | $848.90M | +2.7% | -$0.12 | $0.10 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | $810.90M | +4.5% | -$0.28 | -$0.03 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 2, 2026after the close | $885.00M | +2.4% | -$0.12 | $0.12 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $821.50M | +6.6% | -$0.18 | $0.13 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $826.20M | +8.4% | -$0.02 | $0.17 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | $776.00M | +8.2% | -$0.30 | $0.04 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025before the open | $864.40M | +17.5% | -$0.86 | $0.44 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $770.40M | +14.3% | -$0.25 | $0.19 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $762.10M | +14.2% | -$0.12 | $0.21 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | $717.40M | +7.7% | -$0.10 | $0.10 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 26, 2024before the open | $735.40M | +4.0% | -$0.01 | $0.44 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $674.10M | +8.6% | -$0.04 | $0.19 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023before the open | $667.60M | +8.5% | $0.15 | $0.28 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 1, 2023after the close | $666.20M | +11.7% | -$0.20 | $0.08 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 1, 2023before the open | $707.10M | +15.9% | -$0.23 | $0.27 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $620.60M | +11.0% | -$0.28 | -$0.02 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022before the open | $615.40M | – | -$0.21 | -$0.03 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022before the open | $596.20M | – | $0.14 | -$0.09 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | $610.20M | – | – | $0.23 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021after the close | $559.20M | – | -$0.28 | -$0.05 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 20, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 10, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020before the open | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 22, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Surgery Partners's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | FY2026 | $3.35B – $3.45B | $3.35B – $3.45B | Reaffirmed | Aug 10, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $530.00M | $530.00M | Reaffirmed | Aug 10, 2026 |
Guidance vs results
The last range Surgery Partners gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $3.28B – $3.30B | $3.31BΣ4Q | Above range |
Guidance history
Every forecast Surgery Partners put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 10, 2026 | Adjusted EBITDA | FY2026 | $530.00M | Reaffirmed |
| Aug 10, 2026 | revenue | FY2026 | $3.35B – $3.45B | Reaffirmed |
| May 5, 2026 | Adjusted EBITDA | FY2026 | $530.00M | Reaffirmed |
| May 5, 2026 | revenues | FY2026 | $3.35B – $3.45B | Reaffirmed |
| Mar 2, 2026 | Adjusted EBITDA | FY2026 | $530.00M | New |
| Mar 2, 2026 | revenue | FY2026 | $3.35B – $3.45B | New |
| Nov 10, 2025 | Adjusted EBITDA | FY2025 | $535.00M – $540.00M | New |
| Nov 10, 2025 | revenue | FY2025 | $3.28B – $3.30B | New |
| Aug 5, 2025 | Adjusted EBITDA | FY2025 | $555.00M – $565.00M | Reaffirmed |
| Aug 5, 2025 | revenue | FY2025 | $3.30B – $3.45B | Reaffirmed |
| May 12, 2025 | Adjusted EBITDA | FY2025 | $555.00M – $565.00M | Reaffirmed |
| May 12, 2025 | revenues | FY2025 | $3.30B – $3.45B | Reaffirmed |
| Mar 3, 2025 | Adjusted EBITDA | FY2025 | $555.00M – $565.00M | New |
| Mar 3, 2025 | revenue | FY2025 | $3.30B – $3.45B | New |
| Nov 12, 2024 | Adjusted EBITDA | FY2024 | $508.00M | Reaffirmed |
| Nov 12, 2024 | revenues | FY2024 | $3.08B | Reaffirmed |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | $508.00M | Raised |
| Aug 6, 2024 | revenues | FY2024 | $3.08B | Raised |
| May 7, 2024 | Adjusted EBITDA | FY2024 | $505.00M | Raised |
| May 7, 2024 | revenues | FY2024 | $3.05B | New |
| Feb 26, 2024 | Adjusted EBITDA | FY2024 | $495.00M | New |
| Feb 26, 2024 | revenues | FY2024 | $3.00B | New |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $436.00M – $440.00M | Raised |
| Nov 7, 2023 | revenue | FY2023 | $2.75B | New |
| Aug 1, 2023 | Adjusted EBITDA | FY2023 | $435.00M | Raised |
| Aug 1, 2023 | free cash flow | FY2023 | $140.00M | Reaffirmed |
| Aug 1, 2023 | revenue | FY2023 | $2.75B | Reaffirmed |
| May 1, 2023 | Adjusted EBITDA | FY2023 | $430.00M | Raised |
| May 1, 2023 | free cash flow | FY2023 | $140.00M | New |
| Mar 1, 2023 | Adjusted EBITDA | FY2023 | $425.00M | New |
| Mar 1, 2023 | revenues | FY2023 | $2.75B | New |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | $375.00M – $385.00M | Reaffirmed |
| Nov 8, 2022 | revenue | FY2022 | $2.50B – $2.55B | Lowered |
| Aug 2, 2022 | Adjusted EBITDA | FY2022 | $375.00M – $385.00M | Reaffirmed |
| Aug 2, 2022 | revenue | FY2022 | $2.50B – $2.60B | Raised |
| May 3, 2022 | Adjusted EBITDA | FY2022 | $375.00M – $385.00M | Raised |
| May 3, 2022 | revenue | FY2022 | $2.50B – $2.60B | New |
| Feb 28, 2022 | Adjusted EBITDA | FY2022 | $370.00M – $380.00M | New |
| Feb 28, 2022 | revenues | FY2022 | $2.50B | New |
| Nov 2, 2021 | Adjusted EBITDA | FY2021 | $325.00M – $330.00M | New |
| Nov 2, 2021 | revenues | FY2021 | +19% – +21% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Surgery Partners filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- News
- Update
- Results
- Results
- Update
- Results
- Results